PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Research Report 2024

PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Research Report 2024


PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

Highlights

The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2025 and 2030.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PARP (Poly ADP-Ribose Polymerase) Inhibitor.
The PARP (Poly ADP-Ribose Polymerase) Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab

Product Type Insights

Global markets are presented by PARP (Poly ADP-Ribose Polymerase) Inhibitor type, along with growth forecasts through 2030. Estimates on sales and revenue are based on the price in the supply chain at which the PARP (Poly ADP-Ribose Polymerase) Inhibitor are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
PARP (Poly ADP-Ribose Polymerase) Inhibitor segment by Type

Lynparza
Zejula
Rubraca
Talzenna
Other

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the PARP (Poly ADP-Ribose Polymerase) Inhibitor market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the PARP (Poly ADP-Ribose Polymerase) Inhibitor market.
PARP (Poly ADP-Ribose Polymerase) Inhibitor segment by Application
Ovarian Cancer
Breast Cancer
Other

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2019-2030.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the PARP (Poly ADP-Ribose Polymerase) Inhibitor market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of PARP (Poly ADP-Ribose Polymerase) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PARP (Poly ADP-Ribose Polymerase) Inhibitor.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of PARP (Poly ADP-Ribose Polymerase) Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (2019-2030) & (US$ Million)
2.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2019-2030)
2.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Average Price (2019-2030)
2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Ovarian Cancer
2.4.3 Breast Cancer
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) of Manufacturers (2019-2024)
3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue of Manufacturers (2019-2024)
3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Manufacturers (2019-2024)
3.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Type & Application
3.8 Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Date of Enter into This Industry
3.9 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 AstraZeneca
4.1.1 AstraZeneca Company Information
4.1.2 AstraZeneca Business Overview
4.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2019-2024)
4.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
4.1.5 AstraZeneca Recent Developments
4.2 Tesaro
4.2.1 Tesaro Company Information
4.2.2 Tesaro Business Overview
4.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
4.2.5 Tesaro Recent Developments
4.3 Merck & Co
4.3.1 Merck & Co Company Information
4.3.2 Merck & Co Business Overview
4.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2019-2024)
4.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
4.3.5 Merck & Co Recent Developments
4.4 Clovis Oncology
4.4.1 Clovis Oncology Company Information
4.4.2 Clovis Oncology Business Overview
4.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
4.4.5 Clovis Oncology Recent Developments
4.5 Pfizer
4.5.1 Pfizer Company Information
4.5.2 Pfizer Business Overview
4.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
4.5.5 Pfizer Recent Developments
4.6 GSK
4.6.1 GSK Company Information
4.6.2 GSK Business Overview
4.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2019-2024)
4.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
4.6.5 GSK Recent Developments
4.7 Zai Lab
4.7.1 Zai Lab Company Information
4.7.2 Zai Lab Business Overview
4.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2019-2024)
4.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
4.7.5 Zai Lab Recent Developments
5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Scenario by Region
5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2019-2030
5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2019-2024
5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2025-2030
5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2019-2030
5.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2019-2024
5.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2025-2030
5.4 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
5.4.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2030)
5.4.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
5.5.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2030)
5.5.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
5.6.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2030)
5.6.3 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
5.7.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2030)
5.7.3 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
5.8.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2030)
5.8.3 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2019-2030)
6.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2019-2030) & (K Units)
6.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2019-2030)
6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2019-2030)
6.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2019-2030)
6.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2019-2030)
7 Segment by Application
7.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2019-2030)
7.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2019-2030) & (K Units)
7.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2019-2030)
7.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2019-2030)
6.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2019-2030) & (US$ Million)
6.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2019-2030)
7.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2019-2030)
8 Value Chain and Sales Channels Analysis of the Market
8.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Analysis
8.1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process
8.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
8.2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers
9 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Analyzing Market Dynamics
9.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
9.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers
9.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges
9.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
Table 4. Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Volume and Revenue Market Size and CAGR of Manufacturers (2019 Versus 2023)
Table 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) of Manufacturers (2019-2024)
Table 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2019-2024)
Table 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue of Manufacturers (2019-2024)
Table 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers (2019-2024)
Table 10. Global Market PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/Unit) of Manufacturers (2019-2024)
Table 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Ranking, 2022 VS 2023 VS 2024
Table 12. Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. AstraZeneca Company Information
Table 17. AstraZeneca Business Overview
Table 18. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 19. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
Table 20. AstraZeneca Recent Developments
Table 21. Tesaro Company Information
Table 22. Tesaro Business Overview
Table 23. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 24. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
Table 25. Tesaro Recent Developments
Table 26. Merck & Co Company Information
Table 27. Merck & Co Business Overview
Table 28. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 29. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
Table 30. Merck & Co Recent Developments
Table 31. Clovis Oncology Company Information
Table 32. Clovis Oncology Business Overview
Table 33. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 34. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
Table 35. Clovis Oncology Recent Developments
Table 36. Pfizer Company Information
Table 37. Pfizer Business Overview
Table 38. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 39. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
Table 40. Pfizer Recent Developments
Table 41. GSK Company Information
Table 42. GSK Business Overview
Table 43. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 44. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
Table 45. GSK Recent Developments
Table 46. Zai Lab Company Information
Table 47. Zai Lab Business Overview
Table 48. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 49. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
Table 50. Zai Lab Recent Developments
Table 51. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 52. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2019-2024) & (K Units)
Table 53. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2019-2024)
Table 54. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2025-2030) & (K Units)
Table 55. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2025-2030)
Table 56. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2019-2024) & (US$ Million)
Table 57. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2019-2024)
Table 58. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2025-2030) & (US$ Million)
Table 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2025-2030)
Table 60. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 61. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2024) & (K Units)
Table 62. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2025-2030) & (K Units)
Table 63. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 64. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 65. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 66. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2024) & (K Units)
Table 67. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2025-2030) & (K Units)
Table 68. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 69. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 70. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 71. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2024) & (K Units)
Table 72. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2025-2030) & (K Units)
Table 73. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 74. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 75. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 76. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2024) & (K Units)
Table 77. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2025-2030) & (K Units)
Table 78. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 79. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 80. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 81. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2019-2024) & (K Units)
Table 82. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2025-2030) & (K Units)
Table 83. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 84. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 85. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2019-2024) & (K Units)
Table 86. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2025-2030) & (K Units)
Table 87. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2019-2024)
Table 88. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2025-2030)
Table 89. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2019-2024) & (US$ Million)
Table 90. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2025-2030) & (US$ Million)
Table 91. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2019-2024)
Table 92. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2025-2030)
Table 93. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2019-2024) & (USD/Unit)
Table 94. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2025-2030) & (USD/Unit)
Table 95. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2019-2024) & (K Units)
Table 96. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2025-2030) & (K Units)
Table 97. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2019-2024)
Table 98. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2025-2030)
Table 99. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2019-2024) & (US$ Million)
Table 100. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2025-2030) & (US$ Million)
Table 101. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2019-2024)
Table 102. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2025-2030)
Table 103. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2019-2024) & (USD/Unit)
Table 104. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2025-2030) & (USD/Unit)
Table 105. Key Raw Materials
Table 106. Raw Materials Key Suppliers
Table 107. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
Table 108. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List
Table 109. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
Table 110. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers
Table 111. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints
Table 112. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. PARP (Poly ADP-Ribose Polymerase) InhibitorProduct Picture
Figure 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million), 2019 VS 2023 VS 2030
Figure 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (2019-2030) & (US$ Million)
Figure 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2019-2030) & (K Units)
Figure 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/Unit) & (2019-2030)
Figure 9. Lynparza Product Picture
Figure 10. Zejula Product Picture
Figure 11. Rubraca Product Picture
Figure 12. Talzenna Product Picture
Figure 13. Other Product Picture
Figure 14. Ovarian Cancer Product Picture
Figure 15. Breast Cancer Product Picture
Figure 16. Other Product Picture
Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers in 2023
Figure 18. Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Sites & Headquarters
Figure 19. Global Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Date of Enter into This Industry
Figure 20. Global Top 5 and 10 PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue in 2023
Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region in 2023
Figure 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region in 2023
Figure 25. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country in 2023
Figure 26. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2019-2030)
Figure 27. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2019-2030)
Figure 28. U.S. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country in 2023
Figure 31. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2019-2030)
Figure 32. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2019-2030)
Figure 33. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country in 2023
Figure 39. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2019-2030)
Figure 40. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2019-2030)
Figure 41. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. China Taiwan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Indonesia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Thailand PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Malaysia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country in 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings